Trial · NCT00729690

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

NCT00729690, Phase 3, Completed, Asokumar Buvanendran; results first posted 2012-12-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement. Trials, record NCT00729690. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00729690

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
NCT number: NCT00729690
Status: Completed
Phases: Phase 3
Enrollment: 48 participants, actual
Lead sponsor: Asokumar Buvanendran
Conditions: PAIN
Interventions: Pregabalin, Pregabalin, Placebo
First posted: 2008-08-07
Last updated: 2012-12-19
Results first posted: 2012-12-19

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	NRS Pain Score AUC (NRS*hr) - 1st 24 Hours	24 hours	Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 24 hours after initial dose (0-24hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.
Primary	NRS Pain Score AUC (NRS*hr) - 1st 12 Hours	12 hours Post dose	Numerical Response scale NRS(0-10) Pain scores were collected every 4 hours after the initial dose and the Area Under the Curve (AUC) calculated. Calculated for the 1st 12 hours after initial dose (0-12hr). AUC measured in NRS pain score points per hour (NRS\*hr). Larger AUC values indicate higher levels of reported pain.
Secondary	Active Knee Flexion	PostOp day 2	The degree of active knee flexion (ROM) tolerated by the patient will be assessed at days 1 and 2 post-surgery. Active flexion is the unassisted moment of the joint by the subject. On postoperative (PostOp) day 2
Secondary	Passive Knee Flexion	PostOp day 2	Passive flexion is the moment of the joint with the assistance of a clinician (The clinician or therapist physically hold and moves the knee through it's range of motion).

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	NRS Pain Score AUC (NRS*hr) - 1st 24 Hours	24 hours	All Completed Patients were included in the analysis.	Area (NRS*hr)	MEAN
SECONDARY	Active Knee Flexion	PostOp day 2	All completed patients used.	Degrees	MEAN
PRIMARY	NRS Pain Score AUC (NRS*hr) - 1st 12 Hours	12 hours Post dose	All Completed Patients	Area (NRS*hr)	MEAN
SECONDARY	Passive Knee Flexion	PostOp day 2	All Completed Patients were used	Degrees	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
NRS Pain Score AUC (NRS*hr) - 1st 24 Hours	1 Multi-Dose Pregabalin	70.4	Standard Deviation 34.4	Area (NRS*hr)
NRS Pain Score AUC (NRS*hr) - 1st 24 Hours	2 Single-dose Pregabalin	59.6	Standard Deviation 31.1	Area (NRS*hr)
NRS Pain Score AUC (NRS*hr) - 1st 24 Hours	3 Placebo	73.4	Standard Deviation 34.6	Area (NRS*hr)
Active Knee Flexion	1 Multi-Dose Pregabalin	78.1	Standard Deviation 10.6	Degrees
Active Knee Flexion	2 Single-dose Pregabalin	80.5	Standard Deviation 10.1	Degrees
Active Knee Flexion	3 Placebo	80.5	Standard Deviation 7.0	Degrees
NRS Pain Score AUC (NRS*hr) - 1st 12 Hours	1 Multi-Dose Pregabalin	30.1	Standard Deviation 15.6	Area (NRS*hr)
NRS Pain Score AUC (NRS*hr) - 1st 12 Hours	2 Single-dose Pregabalin	22.7	Standard Deviation 16.9	Area (NRS*hr)
NRS Pain Score AUC (NRS*hr) - 1st 12 Hours	3 Placebo	27.7	Standard Deviation 16.7	Area (NRS*hr)
Passive Knee Flexion	1 Multi-Dose Pregabalin	86.5	Standard Deviation 15.3	Degrees

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	1 Multi-Dose Pregabalin	16
Overall Study	STARTED	2 Single-dose Pregabalin	16
Overall Study	STARTED	3 Placebo	16
Overall Study	COMPLETED	1 Multi-Dose Pregabalin	16
Overall Study	COMPLETED	2 Single-dose Pregabalin	14
Overall Study	COMPLETED	3 Placebo	14
Overall Study	NOT COMPLETED	1 Multi-Dose Pregabalin	0
Overall Study	NOT COMPLETED	2 Single-dose Pregabalin	2
Overall Study	NOT COMPLETED	3 Placebo	2

Source ClinicalTrials.gov

Adverse events3

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Pruritus	Skin and subcutaneous tissue disorders	1 Multi-Dose Pregabalin	2	16	2
other	Pruritus	Skin and subcutaneous tissue disorders	2 Single-dose Pregabalin	3	16	3
other	Pruritus	Skin and subcutaneous tissue disorders	3 Placebo	7	16	7

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	1 Multi-Dose Pregabalin
Total, all-cause mortality	2 Single-dose Pregabalin
Total, all-cause mortality	3 Placebo
Total, other adverse events	1 Multi-Dose Pregabalin	2	16
Total, other adverse events	2 Single-dose Pregabalin	3	16
Total, other adverse events	3 Placebo	7	16
Total, serious adverse events	1 Multi-Dose Pregabalin	0	16
Total, serious adverse events	2 Single-dose Pregabalin	0	16
Total, serious adverse events	3 Placebo	0	16

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22156332	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00729690

GET https://conductscience.org/api/trials/v1/NCT00729690/registered

API reference For AI assistants